Limited Stage Small Cell Lung Cancer Treatment Study

Clinical Trial Title

Chemoradiation with or without atezolizumab in treating patients with limited stage small cell lung cancer.

Clinical Trial Protocol Description:

This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy X-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemoradiation with or without atezolizumab may work better in treating patients with limited stage small cell lung cancer.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have pathologically (histologically or cytologically) proven diagnosis of limited stage small cell lung cancer.
  • Have had measurable disease.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 30 days prior to registration.

You will be excluded from the study if any of the following criteria apply to you:

  • Have clinical or radiological evidence of metastatic disease.

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Gaurav Marwaha, MD

Contact Information

Rush Cancer Center Clinical Trials Office